INKT (MiNK Therapeutics) OCF Yield %: -10.85 (As of Jun. 30, 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.69
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics OCF Yield %?

MiNK Therapeutics INKT -1.85% 34 OCF Yield % is -10.85 as of Jun. 30, 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, MiNK Therapeutics ranks worse than 55.37% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, MiNK Therapeutics's Trailing 12-Month Cash Flow from Operations is $-6.32 Mil, and Market Cap is $58.24 Mil. Therefore, MiNK Therapeutics's OCF Yield % for today is -10.85%.

The historical rank and industry rank for MiNK Therapeutics's OCF Yield % or its related term are showing as below:

INKT' s OCF Yield % Range Over the Past 10 Years
Min: -10.85   Med: 0   Max: -10.43
Current: -10.85


During the past 7 years, the highest OCF Yield % of MiNK Therapeutics was -10.43%. The lowest was -10.85%. And the median was %.

INKT's OCF Yield % is ranked worse than
55.37% of 1416 companies
in the Biotechnology industry
Industry Median: -8.185 vs INKT: -10.85

MiNK Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


MiNK Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


MiNK Therapeutics OCF Yield % Related Terms


MiNK Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics OCF Yield % Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -8.59 -21.35 -42.58 -34.60 -11.29

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.65 -21.29 -5.84 -15.81 -13.25

INKT vs BOLD, FLNA, DWTX: OCF Yield % Comparison

For the Biotechnology subindustry, MiNK Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's OCF Yield % falls into.


INKT
34GF Score
MiNK Therapeutics Inc INKT
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

MiNK Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-5.925 / 52.4719
=-11.29%

MiNK Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-1.733 * 4 / 52.32357
=-13.25%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -10.85 mean?
MiNK Therapeutics (INKT) has a OCF Yield % of -10.85 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MiNK Therapeutics and its competitors. According to the industry distribution chart, MiNK Therapeutics ranks #784 out of 1416 companies in the Biotechnology industry, placing it in the top 55.4%.
Is MiNK Therapeutics' OCF Yield % too high?
MiNK Therapeutics' current OCF Yield % is -10.85. Based on the distribution chart, MiNK Therapeutics ranks #784 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' OCF Yield % compare to BOLD and FLNA?
According to the Biotechnology industry distribution chart, MiNK Therapeutics ranks #784 out of 1416 companies for OCF Yield %. This places MiNK Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current OCF Yield % is -10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current OCF Yield % of -10.85. The current OCF Yield % is -10.85. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current OCF Yield % is -10.85 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.69
Price